Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding

Charlotte Mérie; Lars Køber; Peter Skov Olsen; Charlotte Andersson; Gunnar Gislason; Jan Skov Jensen; Christian Torp-Pedersen

doi:10.1001/jama.2012.54506

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding

Charlotte Mérie, Lars Køber, Peter Skov Olsen, Charlotte Andersson, Gunnar Gislason, Jan Skov Jensen, Christian Torp-Pedersen

213 Citations (Scopus)

Abstract

The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.

Original language	English
Journal	J A M A: The Journal of the American Medical Association
Volume	308
Issue number	20
Pages (from-to)	2118-25
Number of pages	8
ISSN	0098-7484
DOIs	https://doi.org/10.1001/jama.2012.54506
Publication status	Published - 2012

Keywords

Aged
Aged, 80 and over
Anticoagulants
Aortic Valve
Cardiovascular Diseases
Denmark
Drug Administration Schedule
Female
Follow-Up Studies
Heart Defects, Congenital
Heart Valve Diseases
Heart Valve Prosthesis Implantation
Hemorrhage
Humans
Incidence
Male
Middle Aged
Registries
Risk
Stroke
Thromboembolism
Warfarin

Access to Document

10.1001/jama.2012.54506

Cite this

Mérie, C., Køber, L., Skov Olsen, P., Andersson, C., Gislason, G., Skov Jensen, J., & Torp-Pedersen, C. (2012). Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. J A M A: The Journal of the American Medical Association, 308(20), 2118-25. https://doi.org/10.1001/jama.2012.54506

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. / Mérie, Charlotte; Køber, Lars ; Skov Olsen, Peter et al.
In: J A M A: The Journal of the American Medical Association, Vol. 308, No. 20, 2012, p. 2118-25.

Research output: Contribution to journal › Journal article › Research › peer-review

Mérie, C, Køber, L , Skov Olsen, P , Andersson, C , Gislason, G, Skov Jensen, J & Torp-Pedersen, C 2012, 'Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding', J A M A: The Journal of the American Medical Association, vol. 308, no. 20, pp. 2118-25. https://doi.org/10.1001/jama.2012.54506

@article{bb7ef1708b924a0d863fa61a31665170,

title = "Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding",

abstract = "The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.",

keywords = "Aged, Aged, 80 and over, Anticoagulants, Aortic Valve, Cardiovascular Diseases, Denmark, Drug Administration Schedule, Female, Follow-Up Studies, Heart Defects, Congenital, Heart Valve Diseases, Heart Valve Prosthesis Implantation, Hemorrhage, Humans, Incidence, Male, Middle Aged, Registries, Risk, Stroke, Thromboembolism, Warfarin",

author = "Charlotte M{\'e}rie and Lars K{\o}ber and \{Skov Olsen\}, Peter and Charlotte Andersson and Gunnar Gislason and \{Skov Jensen\}, Jan and Christian Torp-Pedersen",

year = "2012",

doi = "10.1001/jama.2012.54506",

language = "English",

volume = "308",

pages = "2118--25",

journal = "J A M A: The Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "20",

}

TY - JOUR

T1 - Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding

AU - Mérie, Charlotte

AU - Køber, Lars

AU - Skov Olsen, Peter

AU - Andersson, Charlotte

AU - Gislason, Gunnar

AU - Skov Jensen, Jan

AU - Torp-Pedersen, Christian

PY - 2012

Y1 - 2012

N2 - The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.

AB - The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.

KW - Aged

KW - Aged, 80 and over

KW - Anticoagulants

KW - Aortic Valve

KW - Cardiovascular Diseases

KW - Denmark

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Heart Defects, Congenital

KW - Heart Valve Diseases

KW - Heart Valve Prosthesis Implantation

KW - Hemorrhage

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Registries

KW - Risk

KW - Stroke

KW - Thromboembolism

KW - Warfarin

UR - https://www.scopus.com/pages/publications/84869792164

U2 - 10.1001/jama.2012.54506

DO - 10.1001/jama.2012.54506

M3 - Journal article

C2 - 23188028

SN - 0098-7484

VL - 308

SP - 2118

EP - 2125

JO - J A M A: The Journal of the American Medical Association

JF - J A M A: The Journal of the American Medical Association

IS - 20

ER -

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this